UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 286

Sortiert nach

Emerging EPO and EPO receptor regulators and signal transducers

Blood, 2015-06, Vol.125 (23), p.3536-3541

2015

Volltextzugriff (PDF)

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibody

Blood, 2010-09, Vol.116 (13), p.2286-2294

2010

Volltextzugriff (PDF)

A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma

Blood, 2017-06, Vol.129 (25), p.3294-3303

2017

Volltextzugriff (PDF)

IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect

Blood, 2011-12, Vol.118 (24), p.6387-6391

2011

Volltextzugriff (PDF)

Ineffective erythropoiesis of TET2 deficiency

Blood, 2018-11, Vol.132 (22), p.2320-2321

Wojchowski, Don M.

2018

Volltextzugriff (PDF)

A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma

Blood, 2012-11, Vol.120 (22), p.4324-4333

2012

Volltextzugriff (PDF)

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia

Blood, 2014-05, Vol.123 (22), p.3390-3397

2014

Volltextzugriff (PDF)

Preclinical characterization of 1-7F9, a novel human anti–KIR receptor therapeutic antibody that augments natural killer–mediated killing of tumor cells

Blood, 2009-09, Vol.114 (13), p.2667-2677

2009

Volltextzugriff (PDF)

A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)

Blood, 2014-05, Vol.123 (22), p.3398-3405

2014

Volltextzugriff (PDF)

Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma

Blood, 2014-05, Vol.123 (22), p.3406-3413

2014

Volltextzugriff (PDF)

MicroRNAs activate natural killer cells through Toll-like receptor signaling

Blood, 2013-06, Vol.121 (23), p.4663-4671

2013

Volltextzugriff (PDF)

Can NKT cells extinguish smoldering myeloma?

Blood, 2013-01, Vol.121 (3), p.418-420

Benson, Don M.

2013

Volltextzugriff (PDF)

Erythroid mRNA processing: a “splice of life”

Blood, 2014-07, Vol.124 (4), p.474-475

Wojchowski, Don M.

2014

Volltextzugriff (PDF)

Human AML activates the aryl hydrocarbon receptor pathway to impair NK cell development and function

Blood, 2018-10, Vol.132 (17), p.1792-1804

2018

Volltextzugriff (PDF)

CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain–engineered monoclonal antibody

Blood, 2010-02, Vol.115 (6), p.1204-1213

2010

Volltextzugriff (PDF)

EPO modulation of cell-cycle regulatory genes, and cell division, in primary bone marrow erythroblasts

Blood, 2007-10, Vol.110 (7), p.2361-2370

2007

Volltextzugriff (PDF)

During EPO or anemia challenge, erythroid progenitor cells transit through a selectively expandable proerythroblast pool

Blood, 2010-12, Vol.116 (24), p.5334-5346

2010

Volltextzugriff (PDF)

Micro-mismanaging sickle cell stress

Blood, 2010-11, Vol.116 (20), p.4040-4042

Wojchowski, Don M.

2010

Volltextzugriff (PDF)

EPO receptor circuits for primary erythroblast survival

Blood, 2008-06, Vol.111 (11), p.5390-5399

2008

Volltextzugriff (PDF)

Core erythropoietin receptor signals for late erythroblast development

Blood, 2006-04, Vol.107 (7), p.2662-2672

2006

Volltextzugriff (PDF)

Spry1 as a novel regulator of erythropoiesis, EPO/EPOR target, and suppressor of JAK2

Blood, 2012-06, Vol.119 (23), p.5522-5531

2012

Volltextzugriff (PDF)

Stem cell factor and interleukin-2/15 combine to enhance MAPK-mediated proliferation of human natural killer cells

Blood, 2009-03, Vol.113 (12), p.2706-2714

2009

Volltextzugriff (PDF)

CNTO 530 functions as a potent EPO mimetic via unique sustained effects on bone marrow proerythroblast pools

Blood, 2009-05, Vol.113 (20), p.4955-4962

2009

Volltextzugriff (PDF)

Erythropoietin modulation of podocalyxin and a proposed erythroblast niche

Blood, 2007-07, Vol.110 (2), p.509-518

2007

Volltextzugriff (PDF)

Lyn kinase promotes erythroblast expansion and late-stage development

Blood, 2006-09, Vol.108 (5), p.1524-1532

2006

Volltextzugriff (PDF)

1 – 25 von 286

Suche als RSS-Feed

Aktive Filter

Zeitschrift / SerieBlood

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(286)
Mit Volltextzugriff
(284)

Publikationsform

Artikel
(286)

Sprache

Englisch
(286)
Japanisch
(21)

Erscheinungsjahr

n.n

Thema

Hematology
(75)
Life Sciences & Biomedicine
(75)
Science & Technology
(75)
Biological And Medical Sciences
(59)
Humans
(53)
Animals
(43)
Medical Sciences
(41)
Mice
(39)
Hematologic And Hematopoietic Diseases
(32)
Female
(26)
Adult
(22)
Male
(22)
Fundamental And Applied Biological Sciences. Psychology
(18)
Middle Aged
(16)
Molecular And Cellular Biology
(14)
Cell Differentiation, Maturation, Development, Hematopoiesis
(12)
Cell Physiology
(12)
Cells, Cultured
(11)
Mice, Transgenic
(11)
Aged
(10)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

Menü

Weitere Dienste

Einstellungen

Emerging EPO and EPO receptor regulators and signal transducers

The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti–PD-1 antibody

A phase 1b study of isatuximab plus lenalidomide and dexamethasone for relapsed/refractory multiple myeloma

IPH2101, a novel anti-inhibitory KIR antibody, and lenalidomide combine to enhance the natural killer cell versus multiple myeloma effect

Ineffective erythropoiesis of TET2 deficiency

A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia

Preclinical characterization of 1-7F9, a novel human anti–KIR receptor therapeutic antibody that augments natural killer–mediated killing of tumor cells

A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)

Idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase-δ, as therapy for previously treated indolent non-Hodgkin lymphoma

MicroRNAs activate natural killer cells through Toll-like receptor signaling

Can NKT cells extinguish smoldering myeloma?

Erythroid mRNA processing: a “splice of life”

Human AML activates the aryl hydrocarbon receptor pathway to impair NK cell development and function

CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain–engineered monoclonal antibody

EPO modulation of cell-cycle regulatory genes, and cell division, in primary bone marrow erythroblasts

During EPO or anemia challenge, erythroid progenitor cells transit through a selectively expandable proerythroblast pool

Micro-mismanaging sickle cell stress

EPO receptor circuits for primary erythroblast survival

Core erythropoietin receptor signals for late erythroblast development

Spry1 as a novel regulator of erythropoiesis, EPO/EPOR target, and suppressor of JAK2

Stem cell factor and interleukin-2/15 combine to enhance MAPK-mediated proliferation of human natural killer cells

CNTO 530 functions as a potent EPO mimetic via unique sustained effects on bone marrow proerythroblast pools

Erythropoietin modulation of podocalyxin and a proposed erythroblast niche

Lyn kinase promotes erythroblast expansion and late-stage development

Aktive Filter

Suchergebnisse filtern